We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Experimental Brain Cancer Drug Disrupts Intracellular Endosome Activity

By LabMedica International staff writers
Posted on 16 Mar 2015
Print article
Cancer researchers have described the mechanism by which the low molecular weight compound 5-Benzylglycinyl-amiloride (UCD38B) disrupts the internal regulation of brain cancer (glioma) cells in a manner that triggers the pathway for programmed cell death (apoptosis).

Chemotherapy rarely succeeds in curing brain cancer due to the existence in the tumor of a subpopulation of non-dividing stem cell-like cells that are unaffected by the treatment. These cells, which reside in tumor regions having negligible or no blood supply and minimal oxygen content, remain quiescent for a time then replicate and regenerate the tumor.

Investigators at the University of California, Davis (USA) have been working with the candidate drug UCD38B, which kills both actively growing and quiescent glioma cells. They described the drug's mechanism of action in the January 29, 2015, online issue of the journal Molecular Pharmacology.

The investigators explained that UCD38B triggered an intracellular process of endocytosis that caused 40%–50% of endosomes containing proteins of the urokinase plasminogen activator system (uPAS) to relocate from the area of the cell membrane to mitochondrial regions in the cytoplasm. Components of uPAS have been found to be highly active in many aggressive cancers, including gliomas, as well as metastatic breast, lung, and pancreatic cancers. The improper re-location of the uPAS enzyme complex caused endosomal “mis-trafficking” which corresponded to mitochondrial depolarization with the release and nuclear translocation of apoptosis-inducing factor (AIF) followed by irreversible caspase-independent cell death.

Preliminary studies carried out with a rodent glioma xenograft model showed that a low molecular weight derivative of UCD38B was very effective in destroying the population of hypoxic glioma cells within the tumor without evidence of adverse effects.

“Understanding the drug mechanism of action of UCD38B and its more potent derivatives is the culmination of many years of work of characterizing the processes causing cancer recurrence and developing molecules that target therapeutically resistant cancer cell types,” said senior author Dr. Fredric Gorin, professor of molecular biosciences at the University of California, Davis. “We are hopeful that this new class of drug will one day become an important adjunct to conventional therapies in fighting these especially difficult-to-treat cancers.”

Related Links:

University of California, Davis


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Unit-Dose Packaging solution
HLX
New
Flow Cytometer
BF – 710
New
Automated Cell Counter
QuadCount

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.